An Open-Label Study to Evaluate the Safety and Tolerability of PCS499 for the treatment of Necrobiosis Lipoidica
-
- STATUS
- Recruiting
-
- participants needed
- 9
Summary
The main purpose of this research study is to test the safety and tolerability of PCS499 when given to individuals at a dose of 300 mg, twice a day for 1 week followed by giving PCS499 to individuals at a dose of 900 mg, twice a day, for remaining treatment period. Male or female patients age 18 to 80 years of age, Biopsy-confirmed diagnosis of NL. Procedures include labs, EKG's, Physical exams, questionnaires and a biopsy if not done with-in 5 years and photographs.
Details
| Condition | Medical Research |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | 03698864 |
| Last Modified on | 19 February 2024 |
Eligibility
How to participate?
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.